Patient characteristics
| . | Patient no. . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Age/Sex | 65/M | 34/M | 47/M | 49/M |
| Primary disease* | MM | CML | MDS | MM |
| Primary treatment† | M, P | H, a-I | none | V, A, D |
| Transplant procedure‡ | I, C, TBI, PSCT | ATG, C, TBI, BMT | I, C, TBI, BMT | C, TBI, BMT, DLI |
| Staging of GVHD2-153 | Liver: 3 | Liver: 0 | Liver: 0 | Liver: 4 |
| Gut: 1 | Gut: 0 | Gut: 2 | Gut: 0 | |
| Skin: 4 | Skin: 4 | Skin: 0 | Skin: 0 | |
| Overall: IV | Overall: III | Overall: II | Overall: IV | |
| Previous GVHD medication2-155 | C, Pl, S | C, Pl, S | C, Pl, S | C, Pl, S |
| IT combination | 2, 2, 4 mg/m2 | 2, 2, 4, 4 mg/m2 | 4, 4, 4, 4 mg/m2 | 4, 4, 4 mg/m2 |
| . | Patient no. . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Age/Sex | 65/M | 34/M | 47/M | 49/M |
| Primary disease* | MM | CML | MDS | MM |
| Primary treatment† | M, P | H, a-I | none | V, A, D |
| Transplant procedure‡ | I, C, TBI, PSCT | ATG, C, TBI, BMT | I, C, TBI, BMT | C, TBI, BMT, DLI |
| Staging of GVHD2-153 | Liver: 3 | Liver: 0 | Liver: 0 | Liver: 4 |
| Gut: 1 | Gut: 0 | Gut: 2 | Gut: 0 | |
| Skin: 4 | Skin: 4 | Skin: 0 | Skin: 0 | |
| Overall: IV | Overall: III | Overall: II | Overall: IV | |
| Previous GVHD medication2-155 | C, Pl, S | C, Pl, S | C, Pl, S | C, Pl, S |
| IT combination | 2, 2, 4 mg/m2 | 2, 2, 4, 4 mg/m2 | 4, 4, 4, 4 mg/m2 | 4, 4, 4 mg/m2 |
MM indicates multiple myeloma; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome.
M indicates melphalan; P, prednisone; H, Hydrea, a-I: α-interferon; V, vincristine; A, Adriamycin; D, dexamethasone.
I indicates idarubicine; C, cyclophosphamide; TBI, total body irradiation; PSCT, allogeneic peripheral stem cell transplantation; ATG, antithymocyte globulin; BMT, allogeneic bone marrow transplantation; DLI, donor lymphocyte infusion.
Each organ system was staged grade 1 through 4 aGVHD according to Glucksberg et al.14 Patients were also given an overall grade of aGVHD (I through IV) based on severity of organ involvement.14
C indicates cyclosporine A; Pl, prednisolone; S, Solu-Medrol (up to 1 g daily for at least 3 days).